From Financial Modeling Prep: 2025-05-20 18:00:00

Illumina, Inc. (NASDAQ: ILMN) partners with Signios Bio to launch a grant for proteomics advancements using next-gen sequencing. Despite a negative P/E ratio of -13.95, Illumina’s positive P/S ratio of 3.09 and EV/Sales ratio of 3.43 reflect confidence in its revenue potential. Piper Sandler maintains an “Overweight” rating, projecting a 71.32% stock price increase.



Read more at Financial Modeling Prep:: Illumina, Inc. (NASDAQ:ILMN) Partners with Signios…